search
Back to results

Braining - Physical Exercise in Psychiatry - Evaluation of Feasibility, and Health Among Patients

Primary Purpose

Mental Disorder

Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Braining
Sponsored by
Region Stockholm
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mental Disorder focused on measuring physical exercise, mental disorders

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient at the psychiatric unit

Exclusion Criteria:

  • Severe mental disorder such as ongoing mania, psychosis, and conditions when high risk of suicide or high risk of violence available according to the assessment of psychiatric staff at the unit.
  • Medical conditions such as heart or lung disease, infection, abstinence where heart rate-increasing physical activity is considered contraindicated due to Medical reasons.
  • Physical disability that makes it impossible to move independently to the gym and performing the indicated exercise in the training sessions.
  • Mental disability which means that you can not participate in group training.
  • Difficulty speaking or understanding the Swedish language.
  • Ongoing heavy substance use.

Sites / Locations

  • Region Stockholm, Liljeholmsberget

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Physical activity

Arm Description

Patients are encouraged to participate in physical exercise at the psychiatric unit

Outcomes

Primary Outcome Measures

Actigraph GT3x
Objectively measured physical activity and sedentary time: Total physical activity as counts/day and time spent in sedentary, low, moderate and vigorous intensity as min/day.
Actigraph GT3x
Objectively measured physical activity and sedentary time: Total physical activity as counts/day and time spent in sedentary, low, moderate and vigorous intensity as min/day.
International Physical Activity Questionnaires (IPAQ)
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
International Physical Activity Questionnaires (IPAQ)
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
Patient Health Questionnaire 9 (PHQ-9)
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.
Patient Health Questionnaire 9 (PHQ-9)
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.
Alcohol Use Disorders Identification Test AUDIT
Self rated alcohol use. Minimum value 0, maximum value 32, where higher values indicate higher alcohol use.
Alcohol Use Disorders Identification Test AUDIT
Self rated alcohol use. Minimum value 0, maximum value 32, where higher values indicate higher alcohol use.
Drug Use Disorders Identification Test DUDIT
Self rated drug use. Minimum value 0, maximum value 44, where higher values indicate higher drug use.
Drug Use Disorders Identification Test DUDIT
Self rated drug use. Minimum value 0, maximum value 44, where higher values indicate higher drug use.
Brunnsviken Brief Quality of Life Questionnaire (BBQ)
Self rated quality of life. Minimum value 0, maximum value 96, where higher values indicate higher quality of life satisfaction.
Brunnsviken Brief Quality of Life Questionnaire (BBQ)
Self rated quality of life. Minimum value 0, maximum value 96, where higher values indicate higher quality of life satisfaction.
Acceptability of treatment among patients
Semi-structured interviews
The Credibility/Expectancy Questionnaire (CEQ)
Self rated Credibility of treatment. Minimum value 3, maximum value 27 for each factor, where higher values indicate greater Credibility/Expectancy of the treatment.
The Client Satisfaction Questionnaire-8 (CSQ-8)
Self rated satisfaction of treatment. Minimum value 8, maximum value 32 where higher values indicate greater satisfaction with the treatment.

Secondary Outcome Measures

Generalised Anxiety Disorder 7-item scale (GAD-7)
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Generalised Anxiety Disorder 7-item scale (GAD-7)
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Insomnia Severity Index (ISI)
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
Insomnia Severity Index (ISI)
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
World health organization disability assessment schedule (WHODAS 2.0)
Self rated disability. Minimum value 0, maximum value 100, where higher values indicate more disability.
World health organization disability assessment schedule (WHODAS 2.0)
Self rated disability. Minimum value 0, maximum value 100, where higher values indicate more disability.
Negative effects questionnaire (NEQ 20)
Self rated negative effects of treatment. Minimum value 0, maximum value 80, where higher values indicate more negative effects.
EuroQol (EQ-5D-5L) VAS
Self-assessment instrument for describing and valuing health. Defines health in terms of five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Also included is an overall health rating on a 0-100 hash-marked, vertical visual analogue scale (EQ-VAS). Assessment the scores from the descriptive component can be reported as a five digit number ranging from 11111 (full health) to 55555 (worst health). A number of methods exist for analysing these five digit profiles. However, frequently they are converted to a single utility index using country specific value sets. A higher index number indicates a poorer self-assessed health.
EuroQol (EQ-5D-5L) VAS
Self-assessment instrument for describing and valuing health. Defines health in terms of five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Also included is an overall health rating on a 0-100 hash-marked, vertical visual analogue scale (EQ-VAS). Assessment the scores from the descriptive component can be reported as a five digit number ranging from 11111 (full health) to 55555 (worst health). A number of methods exist for analysing these five digit profiles. However, frequently they are converted to a single utility index using country specific value sets. A higher index number indicates a poorer self-assessed health.
Affective Self Rating Scale (AS-18)
Self-assessment of symptoms of depression and hypomania/mania. 9 items for depression and 9 items for mania. Score 0-72. A score of over 10 on the depressive or manic/hypomanic subscale should give rise to suspicion of ongoing depression and hypomania/mania respectively. Scores of over 10 on both the depressive and manic/hypomanic scale at the same time give may indicate an affective mixed state.
Affective Self Rating Scale (AS-18)
Self-assessment of symptoms of depression and hypomania/mania. 9 items for depression and 9 items for mania. Score 0-72. A score of over 10 on the depressive or manic/hypomanic subscale should give rise to suspicion of ongoing depression and hypomania/mania respectively. Scores of over 10 on both the depressive and manic/hypomanic scale at the same time give may indicate an affective mixed state.
Blood pressure
systolic and diastolic, mmHg
Blood pressure
systolic and diastolic, mmHg
Body mass index (BMI)
Weight in kg divided by the square of height in m
Body mass index (BMI)
Weight in kg divided by the square of height in m
Waist circumference
Waist circumference, cm
Waist circumference
Waist circumference, cm
Heart rate (HR)
Heart rate, beats per minute
Heart rate (HR)
Heart rate, beats per minute
fasting blood sugar (FBS)
fasting blood sugar, mmol/l
fasting blood sugar (FBS)
fasting blood sugar, mmol/l
Hemoglobin A1c (HbA1c)
Glycated hemoglobin, mmol/mol
hemoglobin A1c (HbA1c)
Glycated hemoglobin, mmol/mol
Blood lipids
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
Blood lipids
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
C-reactive protein (CRP)
Measurement of inflammation and infection, mmol/L
C-reactive protein (CRP)
Measurement of inflammation and infection, mmol/L
Treatment Inventory of costs in patients with psychiatric disorders (TIC-P)
Work and illness measured by section C of Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P)
Treatment Inventory of costs in patients with psychiatric disorders (TIC-P)
Work and illness measured by section C of Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P)
Thyroid releasing hormone (TSH)
Measurement of thyroid function, mUnits/L
Thyroid releasing hormone (TSH)
Thyroid releasing hormone, measurement of thyroid function, mUnits/L
Complete blood count
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Complete blood count
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Blood liver function test
Alanine transaminase (ALT) µkat/L, aspartate transaminase (AST) µkat/L, alkaline phosphatase (ALP) µkat/L albumin g/L, bilirubin µmol/L, gamma-glutamyltransferase (GGT) µkat/L, L-lactate dehydrogenase (LD) µkat/L
Blood liver function test
Alanine transaminase (ALT) µkat/L, aspartate transaminase (AST) µkat/L, alkaline phosphatase (ALP) µkat/L albumin g/L, bilirubin µmol/L, gamma-glutamyltransferase (GGT) µkat/L, L-lactate dehydrogenase (LD) µkat/L

Full Information

First Posted
December 25, 2021
Last Updated
October 6, 2023
Sponsor
Region Stockholm
Collaborators
Karolinska Institutet
search

1. Study Identification

Unique Protocol Identification Number
NCT05186688
Brief Title
Braining - Physical Exercise in Psychiatry - Evaluation of Feasibility, and Health Among Patients
Official Title
Braining Study - Implementation of Physical Activity for Patients and Staff in Specialist Psychiatry, Feasibility on Pilot Unit and Effect Evaluation in Randomized Controlled Multi-center Study.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
March 2, 2022 (Actual)
Primary Completion Date
July 31, 2022 (Actual)
Study Completion Date
September 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Stockholm
Collaborators
Karolinska Institutet

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Physical exercise (PE) shows beneficial effects on somatic and psychiatric symptoms. "Braining" is a clinical invention where psychiatric staff exercise together with patients to help patients start and execute PE regularly. In the present study the feasibility of the intervention will be evaluated, how Braining is perceived, and preliminary effects on health and physical activity among patients. The investigators hypothesize that patients' health and physical activity will increase after participation in Braining at the unit. Braining will be implemented at two psychiatric pilot units in Region Stockholm, Sweden. During 6 months patients will be included and treated in 12 weeks PE intervention periods. To measure feasibility patients will answer self-rating questionnaires and be invited to semi structured interviews after receiving the intervention. Health will be measured by physical examination and blood test as well as self-ratings of depression, anxiety, sleep, hypomania, and quality of life before the intervention, every 4 weeks during the intervention, post the intervention, and at follow-up 12 months post the intervention. Physical activity will be rated before, during, after the intervention and at follow-up 12 months post the intervention using International Physical Activity Questionnaires (IPAQ) and Actigraph. All patients that fulfill inclusion criteria at the units will be invited to participate in the study, approximately 50 individuals in total.
Detailed Description
"Braining" is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training sessions and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan. Braining is unique in that it: Includes trained psychiatric clinical staff exercising together with patients from both out- and inpatient ward units in daily, moderate to vigorous aerobic group training sessions is included in regular healthcare fee, (free of charge) includes a motivational and educational visit (as a group seminar or as an individual visit) at the start and end of a twelve-week exercise intervention includes regular measurements (self-assessment questionnaires, blood samples, physical and mental health examination and education before and after the twelve-week exercise intervention) offers short individual motivating visits before every training session, including assessment of day shape and fitness to participate. In the present study focus is on the feasibility of the intervention, how Braining is perceived, and preliminary effects on health and physical activity among patients. The research questions are: How do patients experience Braining in regards such as feasibility, acceptability, credibility, and effects on health and quality of life? How do patients comply to Braining regarding completed training sessions and measurements? What preliminary effect does Braining have on mental and physical health, quality of life and level of function in participating patients before compared to after short- and long-term exposure? Examined from the following points of view: psychiatric symptoms, such as depression, hypomania, anxiety, insomnia? Somatic symptoms, such as blood pressure, resting heart rate, BMI, waist circumference, occurrence of somatic co-morbidity? Braining is to be implemented at 2 psychiatric care units starting nov 2021. Approximately 50 patients will be included. Planned design is an open trial study with monthly measurements during ongoing intervention (weeks 1, 4, 8 and 12) and one follow-up (12 months post inclusion). Physical activity level is measured with Actigraph and IPAQ 1 week before, 6 weeks in, after the intervention and at follow up. Patients´ experience of Braining is examined with self-assessments and in interviews after the end of the intervention. Data analysis Qualitative analysis: Recorded material from interviews is transcribed and analyzed based on the thematic analysis method according to Braun & Clarke et al 2006). The method aims to understand the individual's perspective in relation to a particular phenomenon and is often used as an inductive hypothesis-generating approach. Continuous data will be analyzed using mixed effects models or t-test, nominal data analyzed mainly with chi2 test. In mixed effects models of differences between groups the interaction effect of group and time will be the central estimate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mental Disorder
Keywords
physical exercise, mental disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Physical activity
Arm Type
Experimental
Arm Description
Patients are encouraged to participate in physical exercise at the psychiatric unit
Intervention Type
Behavioral
Intervention Name(s)
Braining
Intervention Description
"Braining" is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan.
Primary Outcome Measure Information:
Title
Actigraph GT3x
Description
Objectively measured physical activity and sedentary time: Total physical activity as counts/day and time spent in sedentary, low, moderate and vigorous intensity as min/day.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Actigraph GT3x
Description
Objectively measured physical activity and sedentary time: Total physical activity as counts/day and time spent in sedentary, low, moderate and vigorous intensity as min/day.
Time Frame
At follow up 12 months after intervention.
Title
International Physical Activity Questionnaires (IPAQ)
Description
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
International Physical Activity Questionnaires (IPAQ)
Description
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
Time Frame
At follow up 12 months after intervention.
Title
Patient Health Questionnaire 9 (PHQ-9)
Description
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Patient Health Questionnaire 9 (PHQ-9)
Description
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.
Time Frame
At follow up 12 months after intervention.
Title
Alcohol Use Disorders Identification Test AUDIT
Description
Self rated alcohol use. Minimum value 0, maximum value 32, where higher values indicate higher alcohol use.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Alcohol Use Disorders Identification Test AUDIT
Description
Self rated alcohol use. Minimum value 0, maximum value 32, where higher values indicate higher alcohol use.
Time Frame
At follow up 12 months after intervention.
Title
Drug Use Disorders Identification Test DUDIT
Description
Self rated drug use. Minimum value 0, maximum value 44, where higher values indicate higher drug use.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Drug Use Disorders Identification Test DUDIT
Description
Self rated drug use. Minimum value 0, maximum value 44, where higher values indicate higher drug use.
Time Frame
At follow up 12 months after intervention.
Title
Brunnsviken Brief Quality of Life Questionnaire (BBQ)
Description
Self rated quality of life. Minimum value 0, maximum value 96, where higher values indicate higher quality of life satisfaction.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Brunnsviken Brief Quality of Life Questionnaire (BBQ)
Description
Self rated quality of life. Minimum value 0, maximum value 96, where higher values indicate higher quality of life satisfaction.
Time Frame
At follow up 12 months after intervention.
Title
Acceptability of treatment among patients
Description
Semi-structured interviews
Time Frame
At follow up 3-5 months after inclusion
Title
The Credibility/Expectancy Questionnaire (CEQ)
Description
Self rated Credibility of treatment. Minimum value 3, maximum value 27 for each factor, where higher values indicate greater Credibility/Expectancy of the treatment.
Time Frame
Week 1 of treatment
Title
The Client Satisfaction Questionnaire-8 (CSQ-8)
Description
Self rated satisfaction of treatment. Minimum value 8, maximum value 32 where higher values indicate greater satisfaction with the treatment.
Time Frame
post treatment, 12 weeks after enrollment
Secondary Outcome Measure Information:
Title
Generalised Anxiety Disorder 7-item scale (GAD-7)
Description
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Generalised Anxiety Disorder 7-item scale (GAD-7)
Description
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Time Frame
At follow up 12 months after intervention.
Title
Insomnia Severity Index (ISI)
Description
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Insomnia Severity Index (ISI)
Description
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
Time Frame
At follow up 12 months after intervention.
Title
World health organization disability assessment schedule (WHODAS 2.0)
Description
Self rated disability. Minimum value 0, maximum value 100, where higher values indicate more disability.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
World health organization disability assessment schedule (WHODAS 2.0)
Description
Self rated disability. Minimum value 0, maximum value 100, where higher values indicate more disability.
Time Frame
At follow up 12 months after intervention.
Title
Negative effects questionnaire (NEQ 20)
Description
Self rated negative effects of treatment. Minimum value 0, maximum value 80, where higher values indicate more negative effects.
Time Frame
post treatment, 12 weeks after enrollment
Title
EuroQol (EQ-5D-5L) VAS
Description
Self-assessment instrument for describing and valuing health. Defines health in terms of five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Also included is an overall health rating on a 0-100 hash-marked, vertical visual analogue scale (EQ-VAS). Assessment the scores from the descriptive component can be reported as a five digit number ranging from 11111 (full health) to 55555 (worst health). A number of methods exist for analysing these five digit profiles. However, frequently they are converted to a single utility index using country specific value sets. A higher index number indicates a poorer self-assessed health.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
EuroQol (EQ-5D-5L) VAS
Description
Self-assessment instrument for describing and valuing health. Defines health in terms of five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Also included is an overall health rating on a 0-100 hash-marked, vertical visual analogue scale (EQ-VAS). Assessment the scores from the descriptive component can be reported as a five digit number ranging from 11111 (full health) to 55555 (worst health). A number of methods exist for analysing these five digit profiles. However, frequently they are converted to a single utility index using country specific value sets. A higher index number indicates a poorer self-assessed health.
Time Frame
At follow up 12 months after intervention.
Title
Affective Self Rating Scale (AS-18)
Description
Self-assessment of symptoms of depression and hypomania/mania. 9 items for depression and 9 items for mania. Score 0-72. A score of over 10 on the depressive or manic/hypomanic subscale should give rise to suspicion of ongoing depression and hypomania/mania respectively. Scores of over 10 on both the depressive and manic/hypomanic scale at the same time give may indicate an affective mixed state.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Affective Self Rating Scale (AS-18)
Description
Self-assessment of symptoms of depression and hypomania/mania. 9 items for depression and 9 items for mania. Score 0-72. A score of over 10 on the depressive or manic/hypomanic subscale should give rise to suspicion of ongoing depression and hypomania/mania respectively. Scores of over 10 on both the depressive and manic/hypomanic scale at the same time give may indicate an affective mixed state.
Time Frame
At follow up 12 months after intervention.
Title
Blood pressure
Description
systolic and diastolic, mmHg
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Blood pressure
Description
systolic and diastolic, mmHg
Time Frame
At follow up 12 months after intervention.
Title
Body mass index (BMI)
Description
Weight in kg divided by the square of height in m
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Body mass index (BMI)
Description
Weight in kg divided by the square of height in m
Time Frame
At follow up 12 months after intervention.
Title
Waist circumference
Description
Waist circumference, cm
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Waist circumference
Description
Waist circumference, cm
Time Frame
At follow up 12 months after intervention.
Title
Heart rate (HR)
Description
Heart rate, beats per minute
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Heart rate (HR)
Description
Heart rate, beats per minute
Time Frame
At follow up 12 months after intervention.
Title
fasting blood sugar (FBS)
Description
fasting blood sugar, mmol/l
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
fasting blood sugar (FBS)
Description
fasting blood sugar, mmol/l
Time Frame
At follow up 12 months after intervention.
Title
Hemoglobin A1c (HbA1c)
Description
Glycated hemoglobin, mmol/mol
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
hemoglobin A1c (HbA1c)
Description
Glycated hemoglobin, mmol/mol
Time Frame
At follow up 12 months after intervention.
Title
Blood lipids
Description
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Blood lipids
Description
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
Time Frame
At follow up 12 months after intervention.
Title
C-reactive protein (CRP)
Description
Measurement of inflammation and infection, mmol/L
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
C-reactive protein (CRP)
Description
Measurement of inflammation and infection, mmol/L
Time Frame
At follow up 12 months after intervention.
Title
Treatment Inventory of costs in patients with psychiatric disorders (TIC-P)
Description
Work and illness measured by section C of Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P)
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Treatment Inventory of costs in patients with psychiatric disorders (TIC-P)
Description
Work and illness measured by section C of Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P)
Time Frame
At follow up 12 months after intervention.
Title
Thyroid releasing hormone (TSH)
Description
Measurement of thyroid function, mUnits/L
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Thyroid releasing hormone (TSH)
Description
Thyroid releasing hormone, measurement of thyroid function, mUnits/L
Time Frame
At follow up 12 months after intervention.
Title
Complete blood count
Description
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Complete blood count
Description
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Time Frame
At follow up 12 months after intervention.
Title
Blood liver function test
Description
Alanine transaminase (ALT) µkat/L, aspartate transaminase (AST) µkat/L, alkaline phosphatase (ALP) µkat/L albumin g/L, bilirubin µmol/L, gamma-glutamyltransferase (GGT) µkat/L, L-lactate dehydrogenase (LD) µkat/L
Time Frame
Change from inclusion to follow up 3 months after inclusion
Title
Blood liver function test
Description
Alanine transaminase (ALT) µkat/L, aspartate transaminase (AST) µkat/L, alkaline phosphatase (ALP) µkat/L albumin g/L, bilirubin µmol/L, gamma-glutamyltransferase (GGT) µkat/L, L-lactate dehydrogenase (LD) µkat/L
Time Frame
At follow up 12 months after intervention.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient at the psychiatric unit Exclusion Criteria: Severe mental disorder such as ongoing mania, psychosis, and conditions when high risk of suicide or high risk of violence available according to the assessment of psychiatric staff at the unit. Medical conditions such as heart or lung disease, infection, abstinence where heart rate-increasing physical activity is considered contraindicated due to Medical reasons. Physical disability that makes it impossible to move independently to the gym and performing the indicated exercise in the training sessions. Mental disability which means that you can not participate in group training. Difficulty speaking or understanding the Swedish language. Ongoing heavy substance use.
Facility Information:
Facility Name
Region Stockholm, Liljeholmsberget
City
Stockholm
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Braining - Physical Exercise in Psychiatry - Evaluation of Feasibility, and Health Among Patients

We'll reach out to this number within 24 hrs